Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CareDx ( (CDNA) ) has issued an announcement.
On September 26, 2025, CareDx, Inc. reached an agreement in principle to settle a shareholder derivative lawsuit in the U.S. District Court for the Northern District of California, consolidating claims that current and former directors and officers issued materially false and misleading statements about the company’s testing services and failed in their fiduciary oversight duties. On December 9, 2025, the court granted preliminary approval of the proposed settlement, authorized notice to current CareDx shareholders of record as of September 26, 2025, and scheduled a hearing for June 30, 2026 to consider final approval, a step that, if confirmed, would resolve both the federal derivative action and related Delaware Chancery litigation without any direct compensation process for individual shareholders, while potentially reducing ongoing legal uncertainty stemming from these governance and disclosure disputes.
The most recent analyst rating on (CDNA) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.
Spark’s Take on CDNA Stock
According to Spark, TipRanks’ AI Analyst, CDNA is a Outperform.
CareDx’s strong financial performance and positive earnings call are the primary drivers of its stock score. The company’s robust revenue growth and improved profitability, along with strategic product launches and operational enhancements, contribute significantly to its favorable outlook. Technical indicators support a bullish trend, while the valuation remains reasonable. The absence of a dividend yield is a minor consideration.
To see Spark’s full report on CDNA stock, click here.
More about CareDx
CareDx, Inc. is a Delaware-based diagnostics company headquartered in Brisbane, California that provides services and products to the organ transplant recipient community, including diagnostic testing services, products, and digital healthcare software for transplant patients and their care providers.
Average Trading Volume: 1,093,370
Technical Sentiment Signal: Buy
Current Market Cap: $995.7M
For detailed information about CDNA stock, go to TipRanks’ Stock Analysis page.